STOCK TITAN

[Form 4] MARIMED INC. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Jon R. Levine, President, CEO, Director and 10% owner of MariMed Inc. (MRMD), reported transactions on 09/15/2025. He received 89,860 restricted stock units (RSUs) that vest in part on 12/15/2025 and convert one-for-one into common shares. The filing shows 26,374 shares were withheld to satisfy tax obligations related to the RSU vesting, and 89,860 shares were recorded as acquired at $0 in connection with the RSU grant. Following these transactions, Levine directly beneficially owns 20,847,234 and indirectly owns 6,684,640 shares held by the Jon Levine Family Trust, totaling disclosed influence over the issuer.

Jon R. Levine, presidente, CEO, amministratore e proprietario del 10% di MariMed Inc. (MRMD), ha riportato operazioni il 15/09/2025. Ha ricevuto 89.860 unità di azioni restritte (RSU) che maturano in parte il 15/12/2025 e si convertiranno una per una in azioni ordinarie. La documentazione mostra che sono state trattenute 26.374 azioni per soddisfare le obbligazioni fiscali legate al vesting delle RSU, e 89.860 azioni sono state registrate come acquisite a 0 $ in relazione alla concessione delle RSU. Dopo queste operazioni, Levine detiene direttamente 20.847.234 azioni e indirettamente 6.684.640 azioni detenute dal Jon Levine Family Trust, totalizzando l’influenza divulgata sull’emittente.

Jon R. Levine, presidente, director ejecutivo, director y propietario del 10% de MariMed Inc. (MRMD), informó operaciones el 15/09/2025. Recibió 89.860 unidades de acciones restringidas (RSU) que vencen parcialmente el 15/12/2025 y se convertirán una por una en acciones ordinarias. La presentación muestra que se retuvieron 26.374 acciones para satisfacer obligaciones fiscales relacionadas con el vesting de las RSU, y 89.860 acciones se registraron como adquiridas a 0 $ en relación con la concesión de las RSU. Tras estas operaciones, Levine posee directamente 20.847.234 y posee indirectamente 6.684.640 acciones pertenecientes al Jon Levine Family Trust, totalizando la influencia divulgada sobre la sociedad emisora.

Jon R. Levine은 MariMed Inc. (MRMD)의 사장, CEO, 이사 및 10% 지분 보유자로 2025년 9월 15일 거래를 보고했습니다. 그는 부분적으로 2025년 12월 15일에 vesting되는 89,860주의 제한주식단위(RSU)를 받았으며, 1대 1로 보통주로 전환됩니다. 제출서는 RSU vesting과 관련된 세금 의무를 충족하기 위해 26,374주가 보류되었고, RSU 부여와 관련하여 89,860주가 $0에 취득한 것으로 기록되었다고 보여줍니다. 이 거래 후, Levine은 직접적으로 20,847,234주를, Jon Levine Family Trust가 보유한 6,684,640주를 간접 보유하여 발행회사에 대한 공시된 영향력을 총합합니다.

Jon R. Levine, président, PDG, administrateur et propriétaire de 10 % de MariMed Inc. (MRMD), a communiqué des transactions le 15/09/2025. Il a reçu 89 860 unités d’actions restreintes (RSU) qui se vesteront en partie le 15/12/2025 et se convertiront une pour une en actions ordinaires. Le dépôt indique que 26 374 actions ont été retenues pour satisfaire les obligations fiscales liées à la vesting des RSU, et 89 860 actions ont été enregistrées comme acquises à 0 $ dans le cadre de l’attribution des RSU. À la suite de ces transactions, Levine détient directement 20 847 234 actions et indirectement 6 684 640 actions détenues par le Jon Levine Family Trust, totalisant l’influence divulguée sur l’émetteur.

Jon R. Levine, Präsident, CEO, Direktor und 10% Eigentümer von MariMed Inc. (MRMD), meldete Transaktionen am 15.09.2025. Er erhielt 89.860 Restricted Stock Units (RSUs), die teilweise am 15.12.2025 vesten und eins zu eins in Stammaktien umgewandelt werden. Die Einreichung zeigt, dass 26.374 Aktien einbehalten wurden, um steuerliche Verpflichtungen im Zusammenhang mit dem RSU-Vesting zu erfüllen, und 89.860 Aktien wurden im Zusammenhang mit der RSU-Zuteilung zu 0 USD als erworben verzeichnet. Nach diesen Transaktionen besitzt Levine direkt 20.847.234 Aktien und indirekt 6.684.640 Aktien, die vom Jon Levine Family Trust gehalten werden, wodurch der offengelegten Einfluss auf den Emittenten insgesamt zunimmt.

جون ر. ليفين، رئيس مجلس الإدارة والرئيس التنفيذي والعضو والمدير ومالك 10% من MariMed Inc. (MRMD)، أبلغ عن معاملات في 15/09/2025. تلقى 89,860 وحدة أسهم مقيدة (RSUs) تستحق جزئياً في 15/12/2025 وتتحول واحداً إلى واحد إلى أسهم عادية. تُظهر الإيداع أن 26,374 سهماً تم حجبها لتلبية الالتزامات الضريبية المرتبطة بالاستحقاق، وتم تسجيل 89,860 سهماً كمكتسبة بقيمة 0 دولار فيما يتعلق بمنحة RSU. بعد هذه المعاملات، يمتلك ليفين بشكل مباشر 20,847,234 سهماً وبشكل غير مباشر 6,684,640 سهماً مملوكة لصندوق Jon Levine Family Trust، ليصل إجمالي النفوذ المعلن لدى المصدر إلى هذا الحد.

Jon R. Levine, MariMed Inc.(MRMD)的总裁、首席执行官、董事及10%股东,于2025年9月15日披露交易。他收到了89,860股受限性股票单位(RSU),部分在2025年12月15日归属,并将按1比1转换为普通股。申报显示为满足RSU归属相关的税务义务而扣留了26,374股,并在RSU授予相关事项中将89,860股记为以0美元取得。交易完成后,Levine直接持有20,847,234股,间接持有Jon Levine Family Trust所持的6,684,640股,总计对发行人的披露影响。

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Insider RSU grant increases executive alignment; share withholding covered taxes, overall ownership remains substantial.

The report documents an RSU award of 89,860 units granted May 9, 2025, with partial vesting on December 15, 2025. The immediate tax withholding of 26,374 shares reduced net shares delivered but does not change the disclosed level of control: direct beneficial ownership remains above 20.8 million shares while an additional 6.68 million are held indirectly in a family trust. For investors, this is a routine equity compensation event and signals continued executive stake in the company without any cash purchase or sale activity disclosed.

TL;DR: Governance-wise this is a standard executive compensation filing showing retained ownership and use of a family trust.

The Form 4 shows standard disclosure practices: RSUs converting one-for-one to common stock, shares withheld to satisfy tax withholding, and a disclaimer of beneficial ownership for trust-held shares. The filing confirms the reporting person’s roles and indicates customary use of equity awards for alignment. There is no indication of unusual transfer, sale, or derivative activity beyond the RSU grant and withholding.

Jon R. Levine, presidente, CEO, amministratore e proprietario del 10% di MariMed Inc. (MRMD), ha riportato operazioni il 15/09/2025. Ha ricevuto 89.860 unità di azioni restritte (RSU) che maturano in parte il 15/12/2025 e si convertiranno una per una in azioni ordinarie. La documentazione mostra che sono state trattenute 26.374 azioni per soddisfare le obbligazioni fiscali legate al vesting delle RSU, e 89.860 azioni sono state registrate come acquisite a 0 $ in relazione alla concessione delle RSU. Dopo queste operazioni, Levine detiene direttamente 20.847.234 azioni e indirettamente 6.684.640 azioni detenute dal Jon Levine Family Trust, totalizzando l’influenza divulgata sull’emittente.

Jon R. Levine, presidente, director ejecutivo, director y propietario del 10% de MariMed Inc. (MRMD), informó operaciones el 15/09/2025. Recibió 89.860 unidades de acciones restringidas (RSU) que vencen parcialmente el 15/12/2025 y se convertirán una por una en acciones ordinarias. La presentación muestra que se retuvieron 26.374 acciones para satisfacer obligaciones fiscales relacionadas con el vesting de las RSU, y 89.860 acciones se registraron como adquiridas a 0 $ en relación con la concesión de las RSU. Tras estas operaciones, Levine posee directamente 20.847.234 y posee indirectamente 6.684.640 acciones pertenecientes al Jon Levine Family Trust, totalizando la influencia divulgada sobre la sociedad emisora.

Jon R. Levine은 MariMed Inc. (MRMD)의 사장, CEO, 이사 및 10% 지분 보유자로 2025년 9월 15일 거래를 보고했습니다. 그는 부분적으로 2025년 12월 15일에 vesting되는 89,860주의 제한주식단위(RSU)를 받았으며, 1대 1로 보통주로 전환됩니다. 제출서는 RSU vesting과 관련된 세금 의무를 충족하기 위해 26,374주가 보류되었고, RSU 부여와 관련하여 89,860주가 $0에 취득한 것으로 기록되었다고 보여줍니다. 이 거래 후, Levine은 직접적으로 20,847,234주를, Jon Levine Family Trust가 보유한 6,684,640주를 간접 보유하여 발행회사에 대한 공시된 영향력을 총합합니다.

Jon R. Levine, président, PDG, administrateur et propriétaire de 10 % de MariMed Inc. (MRMD), a communiqué des transactions le 15/09/2025. Il a reçu 89 860 unités d’actions restreintes (RSU) qui se vesteront en partie le 15/12/2025 et se convertiront une pour une en actions ordinaires. Le dépôt indique que 26 374 actions ont été retenues pour satisfaire les obligations fiscales liées à la vesting des RSU, et 89 860 actions ont été enregistrées comme acquises à 0 $ dans le cadre de l’attribution des RSU. À la suite de ces transactions, Levine détient directement 20 847 234 actions et indirectement 6 684 640 actions détenues par le Jon Levine Family Trust, totalisant l’influence divulguée sur l’émetteur.

Jon R. Levine, Präsident, CEO, Direktor und 10% Eigentümer von MariMed Inc. (MRMD), meldete Transaktionen am 15.09.2025. Er erhielt 89.860 Restricted Stock Units (RSUs), die teilweise am 15.12.2025 vesten und eins zu eins in Stammaktien umgewandelt werden. Die Einreichung zeigt, dass 26.374 Aktien einbehalten wurden, um steuerliche Verpflichtungen im Zusammenhang mit dem RSU-Vesting zu erfüllen, und 89.860 Aktien wurden im Zusammenhang mit der RSU-Zuteilung zu 0 USD als erworben verzeichnet. Nach diesen Transaktionen besitzt Levine direkt 20.847.234 Aktien und indirekt 6.684.640 Aktien, die vom Jon Levine Family Trust gehalten werden, wodurch der offengelegten Einfluss auf den Emittenten insgesamt zunimmt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Levine Jon R

(Last) (First) (Middle)
C/O MARIMED INC.
10 OCEANA WAY

(Street)
NORWOOD, MA 02062

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MARIMED INC. [ MRMD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
09/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common stock 09/15/2025 M 89,860 A $0(1) 20,873,608 D
Common stock 09/15/2025 F 26,374(2) D $0.1374 20,847,234 D
Common stock 6,684,640 I By the Jon Levine Family Trust(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (RSU) (1) 09/15/2025 M 89,860 (4) (4) Common Stock, par value $.001 per share 89,860 $0 89,859 D
Explanation of Responses:
1. RSUs convert to shares of common stock on a one-for-one basis.
2. Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs.
3. These shares are held in trust for the benefit of the Reporting Person's spouse and children. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
4. These RSUs were granted on May 9, 2025; the remaining RSUs will vest on December 15, 2025 in accordance with the terms of an award agreement between the Issuer and the Reporting Person.
Remarks:
/s/ Jon R. Levine 09/16/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did MRMD insider Jon R. Levine acquire on 09/15/2025?

He received 89,860 restricted stock units (RSUs) that convert one-for-one into common shares.

How many shares were withheld for taxes in the MRMD Form 4?

26,374 shares were withheld by the issuer to satisfy tax withholding obligations related to RSU vesting.

What is Jon Levine's total reported direct and indirect ownership in MRMD?

The filing shows 20,847,234 shares directly and 6,684,640 shares indirectly held in the Jon Levine Family Trust.

When will the remaining RSUs vest according to the filing?

The remaining RSUs are scheduled to vest on December 15, 2025 per the award agreement.

Were there any cash purchases or sales reported by the insider on this Form 4?

No cash purchases or sales were reported; the transactions reflect RSU vesting and tax withholding.
Marimed

OTC:MRMD

MRMD Rankings

MRMD Latest News

MRMD Latest SEC Filings

MRMD Stock Data

56.49M
280.32M
14.7%
0.24%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States
Norwood